These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 21953853

  • 21. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
    Serrao A, Merli M, Lucani B, Aprile F, Fiori L, Gioia S, Breccia M, Riggio O, Chistolini A.
    Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Results from the OTIS-DVT Registry.
    Spirk D, Husmann M, Willenberg T, Banyai M, Frank U, Baldi T, Amann-Vesti B, Baumgartner I, Kucher N.
    Thromb Haemost; 2011 Feb; 105(2):239-44. PubMed ID: 20886197
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.
    Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD.
    Thromb Haemost; 2014 Jan; 111(1):172-9. PubMed ID: 24154729
    [Abstract] [Full Text] [Related]

  • 26. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V, Bertoletti L, Cucherat M, Jardel S, Grange C, Provencher S, Lega JC.
    PLoS One; 2019 Jan; 14(4):e0214134. PubMed ID: 30933993
    [Abstract] [Full Text] [Related]

  • 27. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M, Koksoy C, Hasan E, Akcalı Y, Karabay O, Filizcan U, TROMBOTEK Study Group.
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [Abstract] [Full Text] [Related]

  • 28. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
    Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti-Hayakawa GG, Montalvão S, Annichino-Bizzacchi JM.
    Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
    [Abstract] [Full Text] [Related]

  • 29. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P, Barbar S, Milan M, Vedovetto V, Pesavento R.
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [Abstract] [Full Text] [Related]

  • 30. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C, Katholing A, Folkerts K, Rietbrock S.
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical characteristics and long-term follow-up of patients with renal vein thrombosis.
    Wysokinski WE, Gosk-Bierska I, Greene EL, Grill D, Wiste H, McBane RD.
    Am J Kidney Dis; 2008 Feb; 51(2):224-32. PubMed ID: 18215700
    [Abstract] [Full Text] [Related]

  • 34. Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants.
    Prandoni P, Ageno W, Mumoli N, Zanatta N, Imberti D, Visonà A, Ciammaichella M, Simioni L, Cappelli R, Bucherini E, Di Nisio M, Avruscio G, Camporese G, Parisi R, Cuppini S, Turatti G, Noventa F, Sarolo L.
    Thromb Res; 2017 May; 153():97-100. PubMed ID: 28364690
    [Abstract] [Full Text] [Related]

  • 35. The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment.
    Vítovec M, Golán L, Roztocil K, Linhart A.
    Vasa; 2009 Aug; 38(3):238-44. PubMed ID: 19736635
    [Abstract] [Full Text] [Related]

  • 36. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
    Cosmi B, Legnani C, Cini M, Favaretto E, Palareti G.
    Thromb Res; 2008 Aug; 122(5):610-7. PubMed ID: 18304616
    [Abstract] [Full Text] [Related]

  • 37. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
    de Groot MR, Njo TL, van Marwijk Kooy M, Büller HR.
    Clin Lab; 2000 Aug; 46(11-12):575-81. PubMed ID: 11109505
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism.
    Prandoni P.
    Adv Exp Med Biol; 2017 Aug; 906():89-100. PubMed ID: 27620306
    [Abstract] [Full Text] [Related]

  • 40. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Wang W, Su Y, Wu C, Sun Y, Dai N, Chen W, Zhang J, Xu Y, Brindis RG, Xu D, Li J.
    BMC Cardiovasc Disord; 2020 Feb 03; 20(1):53. PubMed ID: 32013892
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.